This article is reposted from The American Journal of Emergency Medicine.
Introduction
The coronavirus disease 2019 (COVID-19) pandemic has caused a total of nearly 300,000 deaths worldwide [1]. Pediatric patients PCR-postive for SARS-CoV-2 present differently than adults with 40% either asymptomatic or with URI symptoms and commonly have pharyngeal erythema [2]. A recent systematic review article on COVID-19 reports a low pediatric prevalence [3]. On May 14, the CDC released a Health Advisory on a severe life-threatening complication of pediatric COVID-19 termed Multisystem Inflammatory Syndrome in Children (MIS-C) [4]. We describe a case of MIS-C in a child who presented to our Emergency Department (ED) twice and on the second visit was found to have signs of distributive shock, multi-organ injury and systemic inflammation associated with COVID-19.
Case description
Our patient is an 11-year-old fully immunized female with no past medical history who presented with 4 days of sore throat, malaise, poor appetite, generalized abdominal pain, leg pain, fever and an itchy rash starting on her palms that quickly spread to the trunk and back. On initial presentation to our ED the patient was alert, non-toxic and in no acute distress. Vitals: febrile (39.3 °C) and tachycardic (126). Respiration and blood pressure were within normal limits. Physical exam: mild pharyngeal erythema, no exudates or palatal petechiae, no lymphadenopathy, mild dehydration, and a diffuse reticular, non-blanching papular rash on the bilateral upper extremities and abdomen (sandpaper) with palmar erythema. After a normal chest X-ray the patient’s fever resolved, she felt better, and was discharged with precautions to return if fever persisted or for worsening symptoms.
A follow-up phone call was made the day after discharge with patient and mother reporting minimal improvement and she returned to our ED. Two hours after ED arrival, Vitals: hypotensive (80/38 mmHg), tachypneic (34 b/min), febrile (39.1 °C) and tachycardic (113). Fluid boluses of 2 L failed to normalize BP or HR. EKG: sinus tachycardia and S1Q3T3 without acute ischemia. Troponin and BNP were elevated to 0.112 (≤ 0.010 ng/mL) and 8718 (≤ 125 pg/mL), respectively. An elevated white blood cell count of 14.18 (4.00–10.50 K/uL) with left shift and lymphopenia, normal platelets and increased PT/INR of 21.4 (9.4–12.5 s) and 1.9 (0.8–1.2 ratio), c-reactive protein N300 (0.10–2.80 mg/L), D-dimer 1207 (0–243 ng/mL D-DU), ferritin 1789 (13.00–150.00 ng/mL), lactate dehydrogenase 301 (120–300 U/L), procalcitonin 16.28 (0.00–0.50 ng/mL), and fibrinogen 597 (200–393 mg/dL). BUN 28.0 (5.0–18.0 mg/dL) and creatinine 2.06 (0.53–0.79 mg/dL).
The patient tested PCR positive for SARS-CoV-2. The differential diagnosis was toxic shock syndrome, cytokine storm, hemophagocytic lymphohistiocytosis, septic shock, atypical Kawasaki disease, or cardiogenic shock secondary to myocarditis vs. pulmonary embolism.
The patient was transferred to PICU already on milrinone and norepinephrine, an official echocardiogram: “LV systolic function mildly decreased based on decreased shortening fraction.” Furosemide was given. Empiric antibiotic coverage included ceftaroline, clindamycin and piperacillin-tazobactam. Full-dose anticoagulation with enoxaparin was initiated and the patient was also given Vitamin K to correct elevated PT and INR. IL-6 was elevated to 1449 (0.0–15.5 pg/mL) and tocilizumab, an IL-6 inhibitor, was started along with convalescent plasma and remdesivir. The patient received steroids and IVIG for possible incomplete Kawasaki. She improved dramatically; within < 24 h, she no longer required pressors and was afebrile without tachycardia.
Prior to discharge, EKG and echo were repeated. S1Q3T3 from the initial EKG had resolved. Repeat echo was performed on 5/5/20: “Normal study. LV function improved from previous study. Normal biventricular function. No aneurysms noted in the proximal coronary artery network.” D-dimer was downtrending, troponemia had resolved and BNP was at baseline on discharge. The patient was sent home with instructions to continue with enoxaparin injections for two weeks followed by an appointment with pediatric hematology and pediatric cardiology.
Discussion
This is the first case report in our ED of MIS-C. A case report from India reported a similar presentation of an eight-year-old with sore throat, fever, abdominal pain and rash who was found to have fluid-refractory hypotension requiring pressors [5]. At the time of writing, multiple case reports on COVID-19 and atypical or incomplete Kawasaki disease have been published [6,7]. At least one case report has described a mixed picture of possible Kawasaki with features of MIS-C [5]. Our case described features more consistent with a toxic shock syndrome, but incomplete Kawasaki disease could not be excluded by the patient’s overall clinical picture. It is important to keep Kawasaki disease in mind for potential MIS-C patients because prompt treatment is low risk and may be beneficial [8]. Finally, earlier reports from China and the United States described infants as the most vulnerable pediatric population for severe COVID-19 [9,10]. This case occurred in an 11-year-old and it appears that thus far, MIS-C is more likely to affect children beyond infancy [4].
Conclusion
Emergency Department physicians should consider close follow-up for any pediatric patient presenting with fever > 3 days during the COVID-19 pandemic who is stable for discharge and lacks other associated signs and symptoms of MIS-C.
Acknowledgements
Special thanks to the Kings County Hospital Center Emergency Department staff for their dedication and strength during the COVID-19 pandemic.
References
- Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–4.
- Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. N Engl J Med. 2020;382
(17):1663–5. - Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;109(6):1088–95.
- Centers for Disease Control and Prevention. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). [Accessed 26 May 2020].
- Balasubramanian S, Nagendran TM, Ramachandran B, Ramanan AV. Hyperinflammatory syndrome in a child with COVID-19 treated successfully with intravenous immunoglobulin and tocilizumab. [published online ahead of print, 2020 May 10]. Indian Pediatr. 2020.
- Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study [published online ahead of print, 2020 May 13]. Lancet. 2020.
- Jones VG, Mills M, Suarez D, et al. COVID-19 and Kawasaki disease: novel virus and novel case. [published online ahead of print, 2020 Apr 7]. Hosp Pediatr. 2020.
- Harahsheh AS, Dahdah N, Newburger JW, et al. Missed or delayed diagnosis of Kawasaki disease during the 2019 novel coronavirus disease (COVID-19) pandemic. [published online ahead of print, 2020 May 3]. J Pediatr. 2020.
- Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. [published online ahead of print, 2020 Mar 16]. Pediatrics. 2020.
- Coronavirus disease 2019 in children – United States, February 12–April 2, 2020.
MMWR Morb Mortal Wkly Rep. 2020;69:422–6.
Andrea Greene
Latest posts by Andrea Greene (see all)
- Just Another Fast Track Lip Lac? - September 18, 2020
- Learning in a Low-Volume ED - June 26, 2020
- Toxic shock-like syndrome and COVID-19: A case report of multisystem inflammatory syndrome in children (MIS-C) - June 18, 2020
0 Comments